Read by QxMD icon Read

omega-3 fatty acids and schizophrenia

M Lambert, V Niehaus, C Correll
This review aims to describe the importance of i) detecting individuals at clinical high-risk for psychosis (schizophrenia) or bipolar disorder, especially in children and adolescents, in order to enable early intervention, and ii) evaluating different intervention strategies, especially pharmacotherapy, during the subsyndromal or "prodromal" stages of these severe and often debilitating disorders. The different approaches regarding the psychotic and bipolar clinical high-risk state are discussed, including reasons and evidence for early (pharmacological) intervention and risks of treatment vs...
October 13, 2016: Pharmacopsychiatry
Matteo M Pusceddu, Philip Kelly, Catherine Stanton, John F Cryan, Timothy G Dinan
OBJECTIVE: The impact of lifetime dietary habits and their role in physical, mental, and social well-being has been the focus of considerable recent research. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a dietary constituent have been under the spotlight for decades. n-3 PUFAs constitute key regulating factors of neurotransmission, neurogenesis, and neuroinflammation and are thereby fundamental for development, functioning and ageing of the CNS. Of note is the fact that these processes are altered in various psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), depression and Alzheimer...
September 8, 2016: International Journal of Neuropsychopharmacology
Paola Bozzatello, Elena Brignolo, Elisa De Grandi, Silvio Bellino
A new application for omega-3 fatty acids has recently emerged, concerning the treatment of several mental disorders. This indication is supported by data of neurobiological research, as highly unsaturated fatty acids (HUFAs) are highly concentrated in neural phospholipids and are important components of the neuronal cell membrane. They modulate the mechanisms of brain cell signaling, including the dopaminergic and serotonergic pathways. The aim of this review is to provide a complete and updated account of the empirical evidence of the efficacy and safety that are currently available for omega-3 fatty acids in the treatment of psychiatric disorders...
2016: Journal of Clinical Medicine
Alaa El-Sayed El-Sisi, Samia Salem Sokkar, Magda El-Sayed El-Sayad, Ehab Sayed Ramadan, Enass Yossef Osman
The implications of oxidative stress and neuro-inflammation in the pathogenesis of schizophrenia have been elucidated. Despite their effectiveness against positive symptoms of schizophrenia, antipsychotics have limited effectiveness against negative and cognitive symptoms and are associated with remarkable adverse effects. The use of celecoxib or omega-3 in schizophrenia may have beneficial effects. This study aimed to evaluate the possible efficacies of celecoxib, omega-3 or the combination of celecoxib+risperidone and omega-3+ risperidone compared to risperidone on the behavior and brain biochemistry in rats...
August 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Natalie Parletta, Dorota Zarnowiecki, Jihyun Cho, Amy Wilson, Nicholas Procter, Andrea Gordon, Svetlana Bogomolova, Kerin O'Dea, John Strachan, Matt Ballestrin, Andrew Champion, Barbara J Meyer
Cardiovascular disease (CVD) is higher in people with mental illness and is associated with a 30 year higher mortality rate in this population. Erythrocyte docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA) (omega-3 index)≤4% is a marker for increased mortality risk from CVD while >8% is protective. Omega-3 polyunsaturated fatty acids are also important for brain function and may ameliorate symptoms of mental illness. We investigated the erythrocyte omega-3 index in people with mental illness...
July 2016: Prostaglandins, Leukotrienes, and Essential Fatty Acids
L Souaiby, R Gaillard, M-O Krebs
INTRODUCTION: Prognosis of schizophrenia has not significantly improved despite extensive research. There is often a relatively long delay between onset of symptoms and treatment initiation. Lately, duration of untreated psychosis (DUP), the time between the onset of psychosis and initiation of treatment, has been one of the most studied variables in patients presenting for a first psychotic episode in order to evaluate the impact of early intervention on the prognosis of schizophrenia...
August 2016: L'Encéphale
D F Levey, E M Niculescu, H Le-Niculescu, H L Dainton, P L Phalen, T B Ladd, H Weber, E Belanger, D L Graham, F N Khan, N P Vanipenta, E C Stage, A Ballew, M Yard, T Gelbart, A Shekhar, N J Schork, S M Kurian, G E Sandusky, D R Salomon, A B Niculescu
Women are under-represented in research on suicidality to date. Although women have a lower rate of suicide completion than men, due in part to the less-violent methods used, they have a higher rate of suicide attempts. Our group has previously identified genomic (blood gene expression biomarkers) and clinical information (apps) predictors for suicidality in men. We now describe pilot studies in women. We used a powerful within-participant discovery approach to identify genes that change in expression between no suicidal ideation (no SI) and high suicidal ideation (high SI) states (n=12 participants out of a cohort of 51 women psychiatric participants followed longitudinally, with diagnoses of bipolar disorder, depression, schizoaffective disorder and schizophrenia)...
June 2016: Molecular Psychiatry
Sung-Wan Kim, Min Jhon, Jae-Min Kim, Stefan Smesny, Simon Rice, Michael Berk, Claudia M Klier, Patrick D McGorry, Miriam R Schäfer, G Paul Amminger
This study investigated the relationship between erythrocyte membrane fatty acid (FA) levels and the severity of symptoms of individuals at ultra-high risk (UHR) for psychosis. Subjects of the present study consisted of 80 neuroleptic-naïve UHR patients. Partial correlation coefficients were calculated between baseline erythrocyte membrane FA levels, measured by gas chromatography, and scores on the Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning Scale, and Montgomery-Asberg Depression Rating Scale (MADRS) after controlling for age, sex, smoking and cannabis use...
2016: PloS One
Muhammad Chanchal Azad, Wendy Diana Shoesmith, Mohammad Al Mamun, Ahmad Faris Abdullah, Daw Khin Saw Naing, Mahadasa Phanindranath, Tanvir Chowdhury Turin
The presence of comorbid physical illnesses especially, cardiovascular diseases (CVD) in schizophrenia is a growing area of concern in recent years. In order to reduce disease burden, to improve quality of life and to provide holistic care, it is important to know about the relationship between schizophrenia and CVD. The objective of this review is to explore the extent of CVD problems, relevant risk factors and potential measures for early diagnosis and prevention of CVD among patients with schizophrenia. Worldwide studies show that patients with schizophrenia have a higher mortality and lower life expectancy than the general population...
February 2016: Asian Journal of Psychiatry
Erik Messamore, Robert K McNamara
A body of translational evidence has implicated dietary deficiency in long-chain omega-3 (LCn-3) fatty acids, including eicosapenaenoic acid (EPA) and docosahexaenoic acid (DHA), in the pathophysiology and potentially etiology of different psychiatric disorders. Case-control studies have consistently observed low erythrocyte (red blood cell) EPA and/or DHA levels in patients with major depressive disorder, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder. Low erythrocyte EPA + DHA biostatus can be treated with fish oil-based formulations containing preformed EPA + DHA, and extant evidence suggests that fish oil supplementation is safe and well-tolerated and may have therapeutic benefits...
2016: Lipids in Health and Disease
Ramon Guixà-González, Matti Javanainen, Maricel Gómez-Soler, Begoña Cordobilla, Joan Carles Domingo, Ferran Sanz, Manuel Pastor, Francisco Ciruela, Hector Martinez-Seara, Jana Selent
Membrane levels of docosahexaenoic acid (DHA), an essential omega-3 polyunsaturated fatty acid (ω-3 PUFA), are decreased in common neuropsychiatric disorders. DHA modulates key cell membrane properties like fluidity, thereby affecting the behaviour of transmembrane proteins like G protein-coupled receptors (GPCRs). These receptors, which have special relevance for major neuropsychiatric disorders have recently been shown to form dimers or higher order oligomers, and evidence suggests that DHA levels affect GPCR function by modulating oligomerisation...
2016: Scientific Reports
Tomasz Pawełczyk, Marta Grancow-Grabka, Magdalena Kotlicka-Antczak, Elżbieta Trafalska, Agnieszka Pawełczyk
Short-term clinical trials of omega-3 polyunsaturated fatty acids (n-3 PUFA) as add-on therapy in patients with schizophrenia revealed mixed results. The majority of these studies used an 8- to 12-week intervention based on ethyl-eicosapentaenoic acid. A randomized placebo-controlled trial was designed to compare the efficacy of 26-week intervention, composed of either 2.2 g/day of n-3 PUFA, or olive oil placebo, with regard to symptom severity in first-episode schizophrenia patients. Seventy-one patients (aged 16-35) were enrolled in the study and randomly assigned to the study arms...
February 2016: Journal of Psychiatric Research
Alejandro Szmulewicz, José M Smith, Marina P Valerio
Despite recent findings on the treatment of schizophrenia, it is an illness still associated with high morbidity and incapacity in social and work domains. There is a growing interest in examining the phases prior to the development of the illness so as to make early interventions that would potentially change its devastating course. The attenuated psychosis syndrome was included in the section III of the last version of the Diagnostic and Statistical Manual of Mental Disorders as a condition in which a patient exhibits mild psychotic symptoms, an intact reality testing and certain degree of social or occupational impairment...
May 2015: Vertex: Revista Argentina de Psiquiatriá
Alexander T Chen, John T Chibnall, Henry A Nasrallah
BACKGROUND: Omega-3 fatty acids have shown promise as an adjunctive treatment for schizophrenia. However, efficacy across studies has been inconsistent. We conducted a meta-analysis of published controlled studies with the goal of detecting different efficacy profiles at various stages of schizophrenia. METHODS: An online search was conducted for randomized, double-blind, placebo-controlled clinical trials, and a meta-analysis was conducted. RESULTS: Ten studies met the criteria for inclusion...
November 2015: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
Christian Knöchel, Martin Voss, Florian Grüter, Gilberto S Alves, Silke Matura, Beate Sepanski, Michael Stäblein, Sofia Wenzler, David Prvulovic, André F Carvalho, Viola Oertel-Knöchel
An increasing body of evidences from preclinical as well as epidemiological and clinical studies suggest a potential beneficial role of dietary intake of omega-3 fatty acids for cognitive functioning. In this narrative review, we will summarize and discuss recent findings from epidemiological, interventional and experimental studies linking dietary consumption of omega-3 fatty acids to cognitive function in healthy adults. Furthermore, affective disorders and schizophrenia (SZ) are characterized by cognitive dysfunction encompassing several domains...
2015: Current Neuropharmacology
Laura Montesinos-Rueda, Josep Cañete-Crespillo, Carolina Palma-Sevillano, Eloi Giné-Serven
INTRODUCTION: Previous studies have shown that erythrocyte cell membranes in patients with schizophrenia contain considerably less omega-3 fatty acids, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), reflecting the lower levels present in neuronal and central nervous system membranes. This phenomenon, linked to genetic, metabolic, or dietary factors, has been associated with the development of schizophrenia and the risk of developing and the severity of metabolic syndrome...
September 2015: Actas Españolas de Psiquiatría
A B Niculescu, D F Levey, P L Phalen, H Le-Niculescu, H D Dainton, N Jain, E Belanger, A James, S George, H Weber, D L Graham, R Schweitzer, T B Ladd, R Learman, E M Niculescu, N P Vanipenta, F N Khan, J Mullen, G Shankar, S Cook, C Humbert, A Ballew, M Yard, T Gelbart, A Shekhar, N J Schork, S M Kurian, G E Sandusky, D R Salomon
Worldwide, one person dies every 40 seconds by suicide, a potentially preventable tragedy. A limiting step in our ability to intervene is the lack of objective, reliable predictors. We have previously provided proof of principle for the use of blood gene expression biomarkers to predict future hospitalizations due to suicidality, in male bipolar disorder participants. We now generalize the discovery, prioritization, validation, and testing of such markers across major psychiatric disorders (bipolar disorder, major depressive disorder, schizoaffective disorder, and schizophrenia) in male participants, to understand commonalities and differences...
November 2015: Molecular Psychiatry
Tomasz Pawełczyk, Elżbieta Trafalska, Agnieszka Pawełczyk, Magdalena Kotlicka-Antczak
AIM: Supplementation with omega-3 PUFA showed efficacy in reducing the risk of transition into psychosis in UHR individuals. It is uncertain whether dietary patterns can be partly responsible for n-3 deficiencies observed in susceptible participants before the diagnosis of schizophrenia. The study was designed to assess differences in omega-3 and omega-6 PUFA consumption in healthy controls (HC), UHR participants and FES patients as well as to verify the hypothesis that dietary changes in PUFA consumption are present before active psychosis develops, that is, in UHR individuals...
August 16, 2015: Early Intervention in Psychiatry
Connie Markulev, Patrick D McGorry, Barnaby Nelson, Hok Pan Yuen, Miriam Schaefer, Alison R Yung, Andrew Thompson, Gregor Berger, Nilufar Mossaheb, Monika Schlögelhofer, Stefan Smesny, Lieuwe de Haan, Anita Riecher-Rössler, Merete Nordentoft, Eric Yu Hai Chen, Swapna Verma, Ian Hickie, G Paul Amminger
AIM: Recent research has indicated that preventative intervention is likely to benefit patients 'at-risk' for psychosis, both in terms of symptom reduction and delay or prevention of onset of threshold psychotic disorder. The strong preliminary results for the effectiveness of omega-3 polyunsaturated fatty acids (PUFAs), coupled with the falling transition rate in ultra high-risk (UHR) samples, mean that further study of such benign, potentially neuroprotective interventions is clinically and ethically required...
August 16, 2015: Early Intervention in Psychiatry
G Paul Amminger, Miriam R Schäfer, Monika Schlögelhofer, Claudia M Klier, Patrick D McGorry
Long-chain omega-3 polyunsaturated fatty acids (PUFAs) are essential for neural development and function. As key components of brain tissue, omega-3 PUFAs play critical roles in brain development and function, and a lack of these fatty acids has been implicated in a number of mental health conditions over the lifespan, including schizophrenia. We have previously shown that a 12-week intervention with omega-3 PUFAs reduced the risk of progression to psychotic disorder in young people with subthreshold psychotic states for a 12-month period compared with placebo...
2015: Nature Communications
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"